$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
舒尼替尼用于肾癌患者术后辅助安全有效
2025-10-19 11:44:20
Check Details
仑伐替尼联合PD-1药物治疗肾癌
2025-10-19 11:44:20
Check Details
卡博替尼治疗晚期前列腺癌患者:II期试验结果
2025-10-19 11:44:20
Check Details
依维莫司适应于舒尼替尼耐药的肾癌患者
2025-10-19 11:44:20
Check Details
索拉非尼肾癌靶向药物
2025-10-19 11:44:20
Check Details
舒尼替尼获批肾癌术后辅助治疗用药
2025-10-19 11:44:20
Check Details
卡博替尼治疗肝细胞癌:3期CELESTIAL研究
2025-10-19 11:44:20
Check Details
卡博替尼一线治疗肾癌优于舒尼替尼
2025-10-19 11:44:20
Check Details
依维莫司肾细胞癌靶向治疗用药
2025-10-19 11:44:20
Check Details
舒尼替尼获批肾癌术后辅助治疗
2025-10-19 11:44:20
Check Details
卡博替尼 vs 依维莫司治疗晚期肾细胞癌
2025-10-19 11:44:20
Check Details
舒尼替尼与干扰素治疗肾癌的效果对比
2025-10-19 11:44:20
Check Details
1
2
...
8175
8176
8177
8178
8179
8180
8181
...
10233
10234
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Etrasimod for Ulcerative Colitis: 2mg Once Daily, Onset Timeline, and Safety Monitoring
2
Hibsago (Bepirovirsen) Japan Approval: CHB Functional Cure and B-Well Data Essentials
3
FDA Approves Isembyld (apitegromab-mstn), the World’s First Skeletal Muscle-Targeted Therapy for SMA
4
Post-Enzalutamide mCRPC: HRR/PARP, PSMA Radioligand, and Chemotherapy Sequencing
5
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
6
Acalabrutinib in CLL/SLL Survival Expectation: ELEVATE-TN and ASCEND Long-Term PFS, OS
7
Bosutinib for CML: Time to Response, BCR-ABL Monitoring, and Molecular Remission
8
Bedaquiline for Drug-Resistant TB: 24-Week Regimen, Combination Duration, and When to Stop or Extend
9
Acalabrutinib Dosing and Combination Regimens: CLL/SLL, MCL, Safety Adjustments
10
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
11
Bosutinib for Ph+ CML: Indications, Dosing Adjustments, and Hepatic/Renal Safety
12
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks